Articles By Cyndi Root

41. U.S. Lawmakers To Add Ebola Drugs To Priority Review Voucher Program 11/3/2014

    Lawmakers in the U.S. seek to add the Ebola virus to the priority review voucher program that extends benefits to pharmaceutical companies for developing treatments for certain diseases.

42. New EMA Guidance On Biosimilars 11/3/2014

    The European Medicines Agency (EMA) has enacted new guidelines to help industry navigate biosimilar regulation. It says that regulators face challenges in regulating biosimilars because, unlike chemical medicines, biologics are nearly impossible to duplicate.

43. Bristol-Myers Squibb's Opdivo Succeeds Again In Lung Cancer Phase 2 Trial 11/3/2014

    Bristol-Myers Squibb (BMS) has succeeded again in the CheckMate -063 Phase 2 trial testing Opdivo (nivolumab) against advanced squamous cell non-small cell lung cancer (NSCLC).

44. Boehringer Ingelheim, Lilly Revise Diabetes Alliance 10/31/2014

    Boehringer Ingelheim and Eli Lilly have revised their Diabetes Alliance in an effort to enhance efficiency and focus on product launches.

45. Bristol-Myers Squibb Acquires Option To Buy F-star Alpha, FS102 For HER2 Cancers 10/31/2014

    Bristol-Myers Squibb Company (BMS) may opt to buy F-star Alpha and its lead HER2 oncology candidate, FS102. The exclusive option to acquire F-star Alpha and its assets was announced in a press release, which disclosed that the aggregate deal is worth $475 million.

46. Takeda Licenses Mersana's Fleximer-ADC Candidate For Onco-Targets 10/31/2014

    Takeda’s Millennium Pharmaceuticals has licensed Mersana Therapeutics’ Fleximer- antibody-drug conjugate (ADC) candidate for oncology indications.

47. FDA Approves Baxter's Obizur For Acquired Hemophilia A 10/29/2014

    Patients with acquired hemophilia A (AHA), a rare bleeding disorder, have a new treatment, as the Food and Drug Administration (FDA) has approved Baxter’s Obizur.

48. Celgene Partners With Sutro On ADCs, Acquires Option To Buy Sutro 10/29/2014

    Celgene Corporation has expanded its partnership with Sutro Biopharma and has obtained an exclusive option to acquire Sutro.

49. WHO Urges More R&D In Tuberculosis 10/28/2014

    Tuberculosis (TB) incidence is higher than previously estimated, according to the World Health Organization (WHO).

50. FDA Accepts Merck's, Sanofi's BLA For Pediatric Hexavalent Vaccine 10/23/2014

    Merck and Sanofi are a step closer to approval of their pediatric hexavalent vaccine, (DTaP5-IPV-Hib-HepB1), as the Food and Drug Administration (FDA) has accepted their Biologics License Application (BLA). The two companies announced the application acceptance in a press release, stating that the pediatric combination vaccine helps protect against six diseases.